Tykerb™ Plus Letrozole Delays Disease Progression In Post-menopausal Women With ErbB2 Positive Metastatic Breast Cancer

News — By on December 15, 2008 at 3:00 am

New results from a study in metastatic breast cancer presented today at the 31st Annual CTRC-AACR San Antonio Breast Cancer Symposium showed that the combination of Tykerb™ (lapatinib ditosylate) plus letrozole, as a first line treatment regimen, provided a significant improvement in delaying disease progression when compared to treatment with Femara® (letrozole) alone.

Please read the complete article and let us know what you think below.

Leave a Reply


Leave a Trackback